Digital.nzAll Technology Signals

A wearable turns gastric signals into clinical evidence

Gastric Alimetry · Auckland-founded · international markets

EARLY COMMERCIALCONTINUOUSLY MONITOREDReviewed 9 October 2026
REALITY CHECK

Is it real?

The non-invasive wearable and analysis system have regulatory clearances and are marketed internationally. Broad clinical adoption, reimbursement and outcome evidence remain the scaling gates.

COMMERCIAL STAGE

Where is it now?

Early commercial regulated medical technology.

The capability behind the signal

A wearable array records gastric electrical activity and combines it with patient symptom data; software and AI analysis help clinicians interpret gastric function.

What supports the assessment

  1. 01

    Regulatory clearances have been secured.

  2. 02

    The system is marketed in New Zealand, the US and UK.

  3. 03

    Adoption and reimbursement vary by health system.

What could it change?

Wearables are moving from consumer wellness into specialist diagnostics and longitudinal clinical evidence.

Why it matters here

This is a strong NZ pathway from university research through medical-device engineering, AI analysis, regulation and entry into much larger health markets.

What it means for the sector

  • Model for regulated deep-tech commercialisation
  • Demand for clinical-data and AI assurance skills
  • Opportunity to validate products in NZ health settings
  • Potential export revenue from high-value devices and software

What New Zealand can do

  • Expand clinical validation
  • Build home-monitoring pathways
  • Pursue reimbursement evidence
  • Partner with overseas hospitals and researchers

What should not be overstated

  • Slow clinical procurement
  • Reimbursement uncertainty
  • Sensitive health-data governance
  • Need for continuing validation

What Digital.nz will watch

  • Clinical adoption
  • Reimbursement
  • Home-care evidence
  • New indications
  • Geographic expansion

Sources behind this signal

01Alimetry FDA clearance↗